Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
Ken O'Day,1 Krithika Rajagopalan,2 Kellie Meyer,1 Andrei Pikalov,2 Antony Loebel21Xcenda, Palm Harbor, FL, 2Sunovion Pharmaceuticals, Marlborough, MA, USABackground: The purpose of this study was to evaluate the long-term cost-effectiveness (including hospitalizations and cardiometabolic con...
Main Authors: | O'Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-09-01
|
Series: | ClinicoEconomics and Outcomes Research |
Online Access: | http://www.dovepress.com/long-term-cost-effectiveness-of-atypical-antipsychotics-in-the-treatme-a14326 |
Similar Items
-
Assessment of Long Term Metabolic Effects of Atypical Antipsychotics in Schizophrenia Patients
by: Cason Nicolae-Marius, et al.
Published: (2019-09-01) -
New atypical antipsychotics for schizophrenia: iloperidone
by: Silvio Caccia, et al.
Published: (2010-02-01) -
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01) -
Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole
by: Topolov Mariyan K., et al.
Published: (2016-03-01) -
THE ROLE OF ATYPICAL ANTIPSYCHOTIC DECREASING AGGRESIVENESS IN SCHIZOPHRENIA
by: Juvita Novia Anggraini Maria
Published: (2013-03-01)